Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease

BACKGROUND AND PURPOSE: Apremilast is an oral nonbiologic medication approved for the treatment of adult patients with active psoriatic arthritis and for patients with moderate to severe plaque psoriasis. This article summarizes the efficacy and safety of apremilast and provides characterization of...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Melodie, Roebuck, Heather L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Supplement Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157723/
https://www.ncbi.nlm.nih.gov/pubmed/27869356
http://dx.doi.org/10.1002/2327-6924.12428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5157723/
https://www.ncbi.nlm.nih.gov/pubmed/27869356
http://dx.doi.org/10.1002/2327-6924.12428

Ejemplares similares